Melody Strattan, DO
Interventional Cardiology · Port Charlotte, FLNPI 1487934097
Payments from drug & device makers
Across 379 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Merck$664
- Boston Scientific$656
- Novartis$568
- Amgen$560
- Johnson & Johnson$493
- plus $4K from 33 others
What the payments were for
- Food & beverage$9,08898%
- Education$2132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 48 | $2,403 |
| Merck | 34 | $664 |
| Boston Scientific | 21 | $656 |
| Novartis | 35 | $568 |
| Amgen | 32 | $560 |
| Johnson & Johnson | 21 | $493 |
| Pfizer | 21 | $375 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 22 | $365 |
| Bayer | 17 | $361 |
| Alnylam Pharmaceuticals Inc. | 16 | $283 |
| Philips North America LLC | 9 | $230 |
| Medtronic | 4 | $215 |
| Astellas Pharma US Inc | 3 | $199 |
| Esperion Therapeutics, Inc. | 10 | $197 |
| AstraZeneca | 13 | $191 |
| E.r. Squibb & Sons, L.L.C. | 10 | $171 |
| Boehringer Ingelheim | 10 | $144 |
| BD | 1 | $133 |
| Sanofi-aventis U.S. LLC | 6 | $129 |
| Biotronik Inc. | 2 | $123 |
| Scpharmaceuticals Inc. | 7 | $121 |
| Abiomed | 3 | $98 |
| Regeneron Healthcare Solutions, Inc. | 5 | $70 |
| Lexicon Pharmaceuticals, Inc. | 4 | $60 |
| Terumo Medical Corporation | 3 | $60 |
| Chiesi USA, Inc. | 4 | $59 |
| Cardiva Medical, Inc. | 2 | $51 |
| Cvrx, Inc. | 2 | $49 |
| Amarin Pharma, Inc. | 2 | $44 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| Angiodynamics, Inc. | 2 | $32 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $21 |
| Stryker | 1 | $20 |
| Novo Nordisk | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Innovation Technologies Inc | 1 | $15 |
| Amryt Pharma Holdings Ltd | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$807
- SUPERA$262
- Supera peripheral stent system$251
- NAVITOR$153
- RotarexS 6 F x 135 cm$133
- Omnilink Elite vascular stent system$129
- XARELTO$121
- BioMonitor$105
How this compares
$9,301 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 518 | $666,876 |
| XareltoRivaroxaban | 130 | $173,856 |
| EntrestoSacubitril/Valsartan | 100 | $151,631 |
| Repatha SureclickEvolocumab | 156 | $143,695 |
| MultaqDronedarone Hcl | 43 | $83,943 |
| JardianceEmpagliflozin | 72 | $67,745 |
| BrilintaTicagrelor | 72 | $66,089 |
| Praluent PenAlirocumab | 60 | $42,552 |
| FarxigaDapagliflozin Propanediol | 25 | $22,295 |
| Metoprolol Succinate | 810 | $10,182 |
| Rosuvastatin Calcium | 491 | $6,062 |
| Ezetimibe | 184 | $5,320 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $5,226 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 151 | $4,175 |
| Atorvastatin Calcium | 382 | $3,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $375 | $666,876518 claims |
| Johnson & JohnsonXarelto | $493 | $173,856130 claims |
| NovartisEntresto | $568 | $151,631100 claims |
| AstraZenecaBrilinta, Farxiga | $191 | $88,38497 claims |
| Sanofi-aventis U.S. LLCMultaq | $129 | $83,94343 claims |
| Boehringer IngelheimJardiance | $144 | $67,74572 claims |
| Esperion Therapeutics, Inc.Nexlizet | $197 | $5,22611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Port Charlotte
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.